


Pharmaceuticals & Biotechnology | Small Cap
Solara Active Pharma Sciences Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency, indicating a low level of debt relative to its assets and equity. Profitability metrics present a varied picture, with good gross profit and operating margins, but concerning returns on equity and net margins which needs to be addressed. Growth metrics are highly variable, with strong earnings per share growth offset by declines in revenue and asset growth. The company's liquidity position appears strained, so improvements are needed to improve financial flexibility. While efficiency ratios also show need for improvement, the company's solvency ratios are strong.
Solara Active Pharma Sciences Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency, indicating a low level of debt relative to its assets and equity. Profitability metrics present a varied picture, with good gross profit and operating margins, but concerning returns on equity and net margins which needs to be addressed. Growth metrics are highly variable, with strong earnings per share growth offset by declines in revenue and asset growth. The company's liquidity position appears strained, so improvements are needed to improve financial flexibility. While efficiency ratios also show need for improvement, the company's solvency ratios are strong.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-340.73
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
-249.32
P/B RATIO
1.48
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
1.21
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
9.25
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹511.1 as on Aug 6, 2026.
The growth metrics present a mixed picture. While earnings per share and net income have shown strong growth, revenue and asset growth rates are declining. This suggests that improvements in profitability are driven by cost management rather than top-line expansion. The company should work towards higher revenue growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -21.58 | 13.88 | -10.73 | -0.39 | 6.62 |
| Operating Profit Growth Rate | -79.02 | 65.43 | -170.9 | -316.84 | -9.22 |
| Earnings Per Share (EPS) Growth | -126.2 | -61.85 | 2458.66 | -100.13 | -1466.67 |
| Asset Growth Rate | 12.66 | -1.56 | -18.9 | -5.06 | 4.53 |
| Net Income Growth Rate | -126.24 | -62.07 | 2477.27 | -100.18 | -800 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.02 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 73.76 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 27.76 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.81 | Neutral | 98.00 | 43.88 | 88.00 |
| 5 | Morepen Laboratories Ltd | 7.12 | 45.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 6 | Alembic Ltd | 7.06 | 7.01 | Undervalued | 90.00 | 4.85 | 317.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 44.01 | Overvalued | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 16.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 9 | Sakar Healthcare Ltd | 6.89 | 67.13 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Hester Biosciences Ltd | 6.54 | 37.59 | Neutral | 87.00 | 61.24 | 57.00 |
| 11 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 12 | Remus Pharmaceuticals Ltd | 5.31 | 25.82 | Neutral | 57.00 | 20.97 | 46.00 |
| 13 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 34.79 | Undervalued | 269.00 | 4.69 | 138.00 |
| 14 | Indoco Remedies Ltd | 5.26 | -21.52 | Neutral | 142.00 | -0.61 | -99.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 47.48 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Wanbury Ltd | 4.65 | 29.43 | Neutral | 88.00 | 18.93 | 43.00 |
| 18 | Solara Active Pharma Sciences Ltd | 4.34 | -249.32 | Neutral | 187.00 | -1.50 | -7.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral